Literature DB >> 17510958

Structure-based virtual ligand screening with LigandFit: pose prediction and enrichment of compound collections.

Matthieu Montes1, Maria A Miteva, Bruno O Villoutreix.   

Abstract

Virtual ligand screening methods based on the structure of the receptor are extensively used to facilitate the discovery of lead compounds. In the present study, we investigated the LigandFit package on four different proteins (coagulation factor VIIa, estrogen receptor, thymidine kinase, and neuraminidase), a relatively large compound collection of 65,560 unique "drug-like" molecules and four focused libraries (1950 molecules each). We performed virtual screening experiments with the large database and evaluated six scoring functions available in the package (DockScore, LigScore1, LigScore2, PLP1, PLP2, and PMF). The results showed that LigandFit is an efficient program, especially when used with LigScore1. Similar computations were carried out using focused libraries. In this situation the LigScore1 scoring function outperformed the other ones on three out of the four proteins tested. Even for the difficult neuraminidase case, the LigandFit/LigScore1 combination was still reasonably successful. Assessment of docking accuracy was also performed and again, we found that LigandFit (with DockScore and the CFF parameters) was performing well. On the basis of these results and observed increased enrichments after LigandFit/Ligscore1 screening on focused libraries, we suggest that using this program as a final step of a hierarchical protocol can be very beneficial to assist lead finding.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510958     DOI: 10.1002/prot.21405

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  8 in total

1.  Integrating docking scores and key interaction profiles to improve the accuracy of molecular docking: towards novel B-RafV600E inhibitors.

Authors:  Chun-Qi Hu; Kang Li; Ting-Ting Yao; Yong-Zhou Hu; Hua-Zhou Ying; Xiao-Wu Dong
Journal:  Medchemcomm       Date:  2017-07-24       Impact factor: 3.597

2.  Exploring NMR ensembles of calcium binding proteins: perspectives to design inhibitors of protein-protein interactions.

Authors:  Adriana Isvoran; Anne Badel; Constantin T Craescu; Simona Miron; Maria A Miteva
Journal:  BMC Struct Biol       Date:  2011-05-12

3.  Neoamphimedine circumvents metnase-enhanced DNA topoisomerase IIα activity through ATP-competitive inhibition.

Authors:  Jessica Ponder; Byong Hoon Yoo; Adedoyin D Abraham; Qun Li; Amanda K Ashley; Courtney L Amerin; Qiong Zhou; Brian G Reid; Philip Reigan; Robert Hromas; Jac A Nickoloff; Daniel V LaBarbera
Journal:  Mar Drugs       Date:  2011-11-18       Impact factor: 6.085

4.  In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.

Authors:  Weng Ieong Tou; Calvin Yu-Chian Chen
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

5.  The isolation and characterization of β-glucogallin as a novel aldose reductase inhibitor from Emblica officinalis.

Authors:  Muthenna Puppala; Jessica Ponder; Palla Suryanarayana; Geereddy Bhanuprakash Reddy; J Mark Petrash; Daniel V LaBarbera
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

6.  AMMOS: Automated Molecular Mechanics Optimization tool for in silico Screening.

Authors:  Tania Pencheva; David Lagorce; Ilza Pajeva; Bruno O Villoutreix; Maria A Miteva
Journal:  BMC Bioinformatics       Date:  2008-10-16       Impact factor: 3.169

7.  MS-DOCK: accurate multiple conformation generator and rigid docking protocol for multi-step virtual ligand screening.

Authors:  Nicolas Sauton; David Lagorce; Bruno O Villoutreix; Maria A Miteva
Journal:  BMC Bioinformatics       Date:  2008-04-10       Impact factor: 3.169

Review 8.  Structure-Based Virtual Screening: From Classical to Artificial Intelligence.

Authors:  Eduardo Habib Bechelane Maia; Letícia Cristina Assis; Tiago Alves de Oliveira; Alisson Marques da Silva; Alex Gutterres Taranto
Journal:  Front Chem       Date:  2020-04-28       Impact factor: 5.221

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.